Author: Jordan Halevy

0

Osimertinib: First-line Oral Treatment for Non-Small-Cell Lung Cancer

The New England Journal of Medicine recently published an article regarding phase three of a clinical trial testing osimertinib, an oral first-line treatment for patients with previously untreated epidermal growth factor receptor (EGFR) mutation-positive, advanced non-small-cell lung cancer (NSCLC). Oncogenic EGFR mutations are correlated with NSCLCs. EGFR, a transmembrane tyrosine kinase, regulates cellular proliferation and […]

Read More →
0

Screening Athletes for Cardiac Risk

The New England Journal of Medicine recently published a study examining cases of sudden cardiac arrest in both competitive and non-competitive sports that occurred in Canada from 2008-2014 in order to determine whether pre-participation screening may have helped in identifying at-risk athletes.   The study used a registry of all out-of-hospital cardiac arrests that occurred […]

Read More →
0

Dabigatran in Antithrombotic therapy

Patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) require treatment with anticoagulation to reduce the risk of thromboembolic events and death. Previous guidelines recommended that these patients receive triple therapy with warfarin, a P2Y12 inhibitor such as clopidogrel or ticagrelor, and aspirin. However, this approach is associated with a significant risk of bleeding. The […]

Read More →